Erasca, Inc. Common Stock
Veridion Score
BETALOW CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ERAS moving today?
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ERAS overview
Related filings and maps
Congress activity in ERAS
No receipt-qualified Congressional disclosure is present for ERAS in the cached public ledger.
ERAS contract awards, year to date.
Public federal awards linked to this ticker.
ERAS lobbying filings, year to date.
Registered lobbying filings matched to Erasca, Inc. Common Stock.